FeesSafety
Pluang+

Labcorp raises guidance, stock jumps; valuation now stretched, rated 'hold' for long-term growth.

Company Fundamentals
29 Oct 2026, 15:15 WIB
Seeking Alpha
View Source
Neutral
Labcorp raises guidance, stock jumps; valuation now stretched, rated 'hold' for long-term growth.

Labcorp Holdings recently raised its earnings guidance, prompting a strong rally in its stock price. While the company is seen as a solid long-term growth opportunity due to its focus on specialized testing, the current price-earnings ratio near 20 is considered high relative to its fundamentals. The analyst rates Labcorp as a 'hold,' suggesting investors wait for better entry points as market enthusiasm cools. The specialized testing segment may help Labcorp withstand broader pricing pressures in the lab testing industry.

Labcorp Holdings is the subject of this update, and here is the Pluang health sector market context for readers as of Oct 29, 2026 18:11 WIB: Out of 150 priced US health stocks, 95 rose and 47 fell today. Notable movers include Novartis AG at USD 160.96 with a 3.13% increase, Sana Biotechnology Inc at USD 2.71 up 3.04%, and Gilead Sciences, Inc. at USD 163.65 rising 2.80%.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App